Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

Maj Linda Selenica, Leif Benner, Steven B. Housley, Barbara Manchec, Daniel C. Lee, Kevin R. Nash, Jay Kalin, Joel A. Bergman, Alan Kozikowski, Marcia N. Gordon, Dave Morgan

Research output: Contribution to journalArticle

Abstract

Introduction: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in humans. Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones. Its substrates include tubulin, heat shock protein 90 and cortactin. Tubastatin A is a selective inhibitor of HDAC6. Modification of tau pathology by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy. Methods: We treated rTg4510 mouse models of tau deposition and non-Transgenic mice with tubastatin (25 mg/kg) or saline (0.9%) from 5 to 7 months of age. Cognitive behavior analysis, histology and biochemical analysis were applied to access the effect of tubastatin on memory, tau pathology and neurodegeneration (hippocampal volume). Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype. We further found that tubastatin reduced the levels of total tau, both histologically and by western analysis. Reduction in total tau levels was positively correlated with memory improvement in these mice. However, there was no impact on phosphorylated forms of tau, either by histology or western analysis, nor was there an impact on silver positive inclusions histologically. Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degradation of tau secondary to increased acetylation of HSP90 or both. These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathology.

Original languageEnglish (US)
Article number12
JournalAlzheimer's Research and Therapy
Volume6
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Histone Deacetylases
Histone Deacetylase Inhibitors
Pathology
Tubulin
Acetylation
Histology
Cortactin
Tauopathies
HSP90 Heat-Shock Proteins
Nuclear Proteins
Silver
Microtubules
Neurodegenerative Diseases
Histones
Inhibition (Psychology)
Therapeutics
Phenotype
Enzymes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Selenica, M. L., Benner, L., Housley, S. B., Manchec, B., Lee, D. C., Nash, K. R., ... Morgan, D. (2014). Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Research and Therapy, 6(1), [12]. https://doi.org/10.1186/alzrt241

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. / Selenica, Maj Linda; Benner, Leif; Housley, Steven B.; Manchec, Barbara; Lee, Daniel C.; Nash, Kevin R.; Kalin, Jay; Bergman, Joel A.; Kozikowski, Alan; Gordon, Marcia N.; Morgan, Dave.

In: Alzheimer's Research and Therapy, Vol. 6, No. 1, 12, 2014.

Research output: Contribution to journalArticle

Selenica, ML, Benner, L, Housley, SB, Manchec, B, Lee, DC, Nash, KR, Kalin, J, Bergman, JA, Kozikowski, A, Gordon, MN & Morgan, D 2014, 'Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition', Alzheimer's Research and Therapy, vol. 6, no. 1, 12. https://doi.org/10.1186/alzrt241
Selenica, Maj Linda ; Benner, Leif ; Housley, Steven B. ; Manchec, Barbara ; Lee, Daniel C. ; Nash, Kevin R. ; Kalin, Jay ; Bergman, Joel A. ; Kozikowski, Alan ; Gordon, Marcia N. ; Morgan, Dave. / Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. In: Alzheimer's Research and Therapy. 2014 ; Vol. 6, No. 1.
@article{2b3b2865e334417dbe7179f650e73a3e,
title = "Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition",
abstract = "Introduction: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in humans. Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones. Its substrates include tubulin, heat shock protein 90 and cortactin. Tubastatin A is a selective inhibitor of HDAC6. Modification of tau pathology by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy. Methods: We treated rTg4510 mouse models of tau deposition and non-Transgenic mice with tubastatin (25 mg/kg) or saline (0.9{\%}) from 5 to 7 months of age. Cognitive behavior analysis, histology and biochemical analysis were applied to access the effect of tubastatin on memory, tau pathology and neurodegeneration (hippocampal volume). Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype. We further found that tubastatin reduced the levels of total tau, both histologically and by western analysis. Reduction in total tau levels was positively correlated with memory improvement in these mice. However, there was no impact on phosphorylated forms of tau, either by histology or western analysis, nor was there an impact on silver positive inclusions histologically. Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degradation of tau secondary to increased acetylation of HSP90 or both. These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathology.",
author = "Selenica, {Maj Linda} and Leif Benner and Housley, {Steven B.} and Barbara Manchec and Lee, {Daniel C.} and Nash, {Kevin R.} and Jay Kalin and Bergman, {Joel A.} and Alan Kozikowski and Gordon, {Marcia N.} and Dave Morgan",
year = "2014",
doi = "10.1186/alzrt241",
language = "English (US)",
volume = "6",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

AU - Selenica, Maj Linda

AU - Benner, Leif

AU - Housley, Steven B.

AU - Manchec, Barbara

AU - Lee, Daniel C.

AU - Nash, Kevin R.

AU - Kalin, Jay

AU - Bergman, Joel A.

AU - Kozikowski, Alan

AU - Gordon, Marcia N.

AU - Morgan, Dave

PY - 2014

Y1 - 2014

N2 - Introduction: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in humans. Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones. Its substrates include tubulin, heat shock protein 90 and cortactin. Tubastatin A is a selective inhibitor of HDAC6. Modification of tau pathology by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy. Methods: We treated rTg4510 mouse models of tau deposition and non-Transgenic mice with tubastatin (25 mg/kg) or saline (0.9%) from 5 to 7 months of age. Cognitive behavior analysis, histology and biochemical analysis were applied to access the effect of tubastatin on memory, tau pathology and neurodegeneration (hippocampal volume). Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype. We further found that tubastatin reduced the levels of total tau, both histologically and by western analysis. Reduction in total tau levels was positively correlated with memory improvement in these mice. However, there was no impact on phosphorylated forms of tau, either by histology or western analysis, nor was there an impact on silver positive inclusions histologically. Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degradation of tau secondary to increased acetylation of HSP90 or both. These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathology.

AB - Introduction: Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in humans. Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones. Its substrates include tubulin, heat shock protein 90 and cortactin. Tubastatin A is a selective inhibitor of HDAC6. Modification of tau pathology by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy. Methods: We treated rTg4510 mouse models of tau deposition and non-Transgenic mice with tubastatin (25 mg/kg) or saline (0.9%) from 5 to 7 months of age. Cognitive behavior analysis, histology and biochemical analysis were applied to access the effect of tubastatin on memory, tau pathology and neurodegeneration (hippocampal volume). Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype. We further found that tubastatin reduced the levels of total tau, both histologically and by western analysis. Reduction in total tau levels was positively correlated with memory improvement in these mice. However, there was no impact on phosphorylated forms of tau, either by histology or western analysis, nor was there an impact on silver positive inclusions histologically. Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degradation of tau secondary to increased acetylation of HSP90 or both. These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathology.

UR - http://www.scopus.com/inward/record.url?scp=84989182910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989182910&partnerID=8YFLogxK

U2 - 10.1186/alzrt241

DO - 10.1186/alzrt241

M3 - Article

VL - 6

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 12

ER -